Clinical Trial Update: DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma [Phase 2]

View source ↗

Summary

This entry describes a Phase 2 trial evaluating DB107-Retroviral Replicating Vector (RRV) in combination with DB107-Flucytosine for recurrent glioblastoma or an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioblastoma

Drugs mentioned

• DB107-Flucytosine (Flucytosine)
• DB107-Retroviral Replicating Vector (RRV) (DB107-Retroviral Replicating Vector)

Snippet

Sponsor: Ashish Shah | Conditions: High Grade Glioma, Anaplastic Astrocytoma | Phase 2 | Status: RECRUITING